Literature DB >> 28987692

Primary malignant tumours in the non-cirrhotic liver.

Dong Ho Lee1, Jeong Min Lee2.   

Abstract

Intrahepatic chlangiocarcinomas (CCs), the second most common primary malignant liver tumours, usually occur in non-cirrhotic liver, and can be classified into three types based on gross morphology: mass-forming; periductal infiltrating; and intraductal growing. Among them, mass-forming intrahepatic CCs are the most common type and characterized by homogeneous mass with an irregular but well-defined margin with peripheral enhancement on late arterial phase and delayed enhancement in central portion of tumours corresponding to the fibrous stroma. Several imaging features such as enhancement pattern and degree of diffusion restriction have been suggested as prognostic markers for mass-forming CCs. Hepatocellular carcinomas (HCCs) are the most common primary malignant liver tumors, and usually arise from the cirrhotic liver. However, approximately 20% of HCCs involve the non-cirrhotic liver (hereafter, non-cirrhotic HCC), and non-cirrhotic HCCs are often detected at an advanced stage due to the lack of surveillance for patients with non-cirrhotic liver. Other primary malignant liver tumours other than CCs and HCCs including angiosarcoma, undifferentiated embryonal sarcoma are quite rare, and imaging diagnosis is often difficult. This review offers a brief overview of epidemiology, risk factors and imaging features of primary malignant tumours in non-cirrhotic liver. Understanding of radiologic appearance and predisposing clinical features as well as differentials of primary malignant tumour in non-cirrhotic liver can be helpful for radiologists to adequately assess these tumours, and subsequently to make optimal management plan.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Cholangiocarcinoma; Mucinous Cystic Neoplasm; Non-cirrhotic Hepatocellular Carcinoma; Noncirrhotic Liver; Rare Primary Hepatic Malignant Tumours

Mesh:

Year:  2017        PMID: 28987692     DOI: 10.1016/j.ejrad.2017.08.030

Source DB:  PubMed          Journal:  Eur J Radiol        ISSN: 0720-048X            Impact factor:   3.528


  21 in total

Review 1.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 2.  Mesenchymal stem cells-based therapy in liver diseases.

Authors:  Heng-Tong Han; Wei-Lin Jin; Xun Li
Journal:  Mol Biomed       Date:  2022-07-27

3.  Genomic analysis of an aggressive case with metastatic intrahepatic mucinous cholangiocarcinoma.

Authors:  Yoshiharu Masaki; Noriyuki Akutsu; Yasushi Adachi; Keisuike Ishigami; Norikazu Iwata; Takao Endo; Yoshifumi Ishii; Yasushi Sasaki; Minoru Nagayama; Yasutoshi Kimura; Hiroshi Nakase
Journal:  Clin J Gastroenterol       Date:  2022-06-14

Review 4.  Radioembolization of Intrahepatic Cholangiocarcinoma: Patient Selection, Outcomes, and Competing Therapies.

Authors:  Joseph Ray Ness; Christopher Molvar
Journal:  Semin Intervent Radiol       Date:  2021-10-07       Impact factor: 1.780

Review 5.  Intrahepatic cholangiocarcinoma: Morpho-molecular pathology, tumor reactive microenvironment, and malignant progression.

Authors:  Alphonse E Sirica; Mario Strazzabosco; Massimiliano Cadamuro
Journal:  Adv Cancer Res       Date:  2020-12-09       Impact factor: 6.242

6.  Can Risk Stratification Based on Ultrasound Elastography of Background Liver Assist CEUS LI-RADS in the Diagnosis of HCC?

Authors:  Jiawu Li; Wenwu Ling; Shuang Chen; Lulu Yang; Lin Ma; Qiang Lu; Yan Luo
Journal:  Front Oncol       Date:  2021-04-30       Impact factor: 6.244

Review 7.  Molecular pathways in viral hepatitis-associated liver carcinogenesis: An update.

Authors:  Gulsum Ozlem Elpek
Journal:  World J Clin Cases       Date:  2021-07-06       Impact factor: 1.337

Review 8.  Non-cirrhotic hepatocellular carcinoma in chronic viral hepatitis: Current insights and advancements.

Authors:  Abhilash Perisetti; Hemant Goyal; Rachana Yendala; Ragesh B Thandassery; Emmanouil Giorgakis
Journal:  World J Gastroenterol       Date:  2021-06-28       Impact factor: 5.742

Review 9.  Hepatocellular carcinoma in non-cirrhotic liver: A comprehensive review.

Authors:  Aakash Desai; Sonia Sandhu; Jin-Ping Lai; Dalbir Singh Sandhu
Journal:  World J Hepatol       Date:  2019-01-27

10.  Angiogenic inflammation and formation of necrosis in the tumor microenvironment influence patient survival after radical surgery for de novo hepatocellular carcinoma in non-cirrhosis.

Authors:  Georgi Atanasov; Karoline Dino; Katrin Schierle; Corinna Dietel; Gabriela Aust; Johann Pratschke; Daniel Seehofer; Moritz Schmelzle; Hans-Michael Hau
Journal:  World J Surg Oncol       Date:  2019-12-12       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.